How Poxet 60 Works: Mechanism and Pharmacological Profile

Poxet 60 contains dapoxetine hydrochloride 60 mg, a short-acting selective serotonin reuptake inhibitor (SSRI). Unlike conventional SSRIs that require daily dosing for depression or anxiety, dapoxetine was engineered specifically for on-demand use in premature ejaculation (PE). Its mechanism centres on blocking the reuptake of serotonin at pre- and post-synaptic receptors, thereby enhancing serotonergic signalling and delaying the ejaculatory reflex.

Click to purchase

Poxet 60含有盐酸达泊西汀60毫克，一种短效选择性5-羟色胺再摄取抑制剂（SSRI）。传统SSRI用于抑郁症或焦虑症时通常需要每日服药，达泊西汀则不同，它专门为早泄（PE）的按需使用而设计。其核心机制是阻断突触前和突触后受体对5-羟色胺的再摄取，从而增强5-羟色胺能信号传导，延迟射精反射。

The pharmacokinetics explain why this molecule suits intermittent use: after oral administration of 60 mg, peak plasma concentration is reached in approximately one hour, and about 95% of the drug is cleared within 24 hours — a profile that minimises cumulative exposure compared with daily SSRIs. For patients and prescribers, this means the effect is confined to the window around sexual activity, rather than imposing a continuous pharmacological load.

药代动力学特征解释了这一分子为何适合间歇性使用：口服60毫克后，血药浓度约1小时达峰，24小时内约95%的药物被清除。与每日服用的SSRI相比，这一特征最大限度地减少了累积暴露。对患者和处方者而言，这意味着药效集中在性活动前后的一段时间内，而非持续施加药理负担。

Clinical Performance: What the Trial Data Show

临床表现：试验数据说明了什么

In controlled trials, dapoxetine 60 mg has demonstrated consistent, dose-dependent improvements in intravaginal ejaculatory latency time (IELT). An integrated analysis of five phase III trials involving 6,081 patients showed that at 12 weeks, mean IELT rose from a baseline of 0.9 minutes to 3.6 minutes with dapoxetine 60 mg, compared with an increase to 1.9 minutes on placebo. Australian regulatory evaluation data reported average IELT increasing from approximately 1.1 minutes at baseline to 4.2 minutes at study endpoint in the 60 mg arm, with significant separation from placebo from the first dose onward.

在对照试验中，达泊西汀60毫克对阴道内射精潜伏期（IELT）表现出一致且剂量依赖性的改善。一项纳入6,081名患者的五项III期试验整合分析显示，治疗12周时，60毫克组平均IELT从基线的0.9分钟升至3.6分钟，安慰剂组仅升至1.9分钟。澳大利亚监管评估数据报告，60毫克组平均IELT从基线约1.1分钟升至研究终点时的4.2分钟，且从首次给药起即与安慰剂显著分离。

Beyond latency, dapoxetine has been associated with improved perceived control over ejaculation and greater sexual satisfaction, with similar efficacy observed in both lifelong and acquired PE. Notably, the clinical literature indicates that dapoxetine does not appear to affect mood or carry signals of anxiety, akathisia, suicidality, or discontinuation syndrome at the doses studied — a meaningful distinction from chronic SSRI use.

除潜伏期外，达泊西汀还与射精控制感改善和性满意度提升相关，且在终身性和获得性早泄中疗效相似。值得注意的是，临床文献表明，在研究剂量下，达泊西汀未显示对情绪产生影响，也没有焦虑、静坐不能、自杀倾向或停药综合征的信号——这与长期使用SSRI有重要区别。

Dosing in Practice: Why 60 mg Is Not a Starting Dose

实际用药：为何60毫克不作为起始剂量

Singapore’s regulatory position is unambiguous: dapoxetine is a prescription-only medicine under the Health Sciences Authority (HSA), and registered products such as Priligy are indicated for PE in men 18 to 64 years of age. The recommended starting dose for all patients is 30 mg, taken approximately 1 to 3 hours before sexual activity, with a maximum frequency of once every 24 hours. Escalation to 60 mg is considered only if the 30 mg effect is insufficient and side effects are acceptable.

新加坡的监管立场明确：达泊西汀是卫生科学局（HSA）管辖下的处方药，Priligy等注册产品适用于18至64岁男性的早泄。所有患者的推荐起始剂量均为30毫克，在性活动前约1至3小时服用，最大频率为每24小时一次。仅在30毫克疗效不足且副作用可耐受时，才考虑增加至60毫克。

This stepwise approach is reinforced by safety data: the incidence and severity of adverse events are higher at 60 mg than at 30 mg, and treatment should not be initiated at the 60 mg dose. Pharmacokinetic caution also applies to specific populations. In CYP2D6 poor metabolisers, exposure to dapoxetine is higher, and escalation to 60 mg should be undertaken cautiously. When dapoxetine is co-administered with moderate CYP3A4 inhibitors, the maximum recommended dose is 30 mg, except in patients verified as extensive CYP2D6 metabolisers.

这种阶梯式方法得到了安全性数据的支持：60毫克的不良事件发生率和严重程度均高于30毫克，且不应以60毫克起始治疗。药代动力学方面的谨慎也适用于特定人群。在CYP2D6慢代谢者中，达泊西汀暴露量更高，增加至60毫克应谨慎进行。与中效CYP3A4抑制剂合用时，最大推荐剂量为30毫克，除非患者被证实为CYP2D6快代谢者。

In the Singapore context, the distinction between original and generic products matters. Poxet 60 is a generic dapoxetine product manufactured in India (Sunrise Remedies), while Priligy is the originator brand registered with HSA. Both contain the same active molecule, but regulatory approval status, supply-chain oversight, and prescription verification differ. Under HSA rules, no legitimate pharmacy in Singapore may dispense dapoxetine without a valid prescription, regardless of whether the product is branded or generic.

在新加坡语境下，原厂产品与仿制产品的区别值得关注。Poxet 60是印度生产的仿制达泊西汀产品（Sunrise Remedies），Priligy则是已在HSA注册的原研品牌。两者含有相同的活性分子，但监管批准状态、供应链监督和处方核验环节不同。根据HSA规定，新加坡任何合法药房均不得在无有效处方的情况下配发达泊西汀，无论产品为原研还是仿制。

Adverse Effects and Tolerability: A Balanced View

不良反应与耐受性：平衡的视角

The tolerability profile of dapoxetine is well characterised. The most commonly reported treatment-emergent adverse events are nausea, dizziness, and headache. In trial data, nausea occurred in approximately 22.2% of patients on 60 mg (versus 11.0% on 30 mg), dizziness in 10.9%, and headache in 5.6% at the 30 mg dose. These effects are typically transient and manageable, but they are dose-related and contribute to the rationale for starting at 30 mg.

达泊西汀的耐受性特征已有充分描述。最常见的不良事件为恶心、头晕和头痛。试验数据显示，60毫克组恶心发生率约22.2%（30毫克组为11.0%），头晕10.9%，30毫克组头痛5.6%。这些反应通常为一过性且可控，但与剂量相关，这也构成了从30毫克起始的理由。

A less common but clinically important consideration is syncope and prodromal symptoms such as lightheadedness. Regulatory data indicate that the frequency of syncope in the dapoxetine clinical programme ranged from 0.06% at 30 mg to 0.23% at 60 mg, and patients should be advised to avoid driving or operating machinery if such symptoms occur. Pre-treatment orthostatic assessment is recommended in the Singapore product information, particularly to identify individuals with a history suggestive of orthostatic reactions.

一个较少见但临床意义重要的考虑是晕厥及前驱症状（如头晕眼花）。监管数据显示，达泊西汀临床项目中晕厥发生率在30毫克时为0.06%，60毫克时为0.23%，应告知患者若出现此类症状应避免驾驶或操作机械。新加坡产品信息建议进行治疗前体位性评估，尤其要识别有体位性反应病史的个体。

On the question of dependence and tolerance, the short-acting, on-demand pharmacology of dapoxetine reduces cumulative exposure, and the clinical literature does not signal a discontinuation syndrome at therapeutic doses. This does not eliminate the need for medical oversight, but it distinguishes dapoxetine from daily SSRIs in terms of the risk profile relevant to intermittent use.

关于依赖性与耐受性，达泊西汀短效、按需的药理学特征减少了累积暴露，临床文献也未提示治疗剂量下存在停药综合征。这并不能免除医疗监督的必要性，但在与间歇使用相关的风险特征上，达泊西汀有别于每日服用的SSRI。